Clinical trials: Allogenic Disease
Graft vs Host Disease
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Background: Chronic graft-versus-host disease (cGVHD) is an immune system disorder that can occur in people who have had a stem cell transplant. cGVHD can affect multiple organs and increase risk of disability and death.
- Trial name
- NCT05531786
- Testing
- Pacritinib
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancy, Myeloid Malignancy
Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
The participants are being asked to take part in this clinical trial because the participant have a lymphoid or myeloid based cancer diagnosis that requires a bone marrow transplant.
- Trial name
- NCT05579769
- Testing
- Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- St. Jude Children's Research Hospital
Hematologic Malignancies
Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets
In the transplant community, there is debate regarding the most appropriate food services for stem cell transplant patients. Recommendations regarding the use of low bacterial diets have been based on theoretical concepts of…
- Trial name
- NCT01687231
- Testing
- Non-neutropenic Diet
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Duke University
Acute Myeloid Leukemia
MG4101 for Refractory or Relapsed AML
This study is a single center, single arm, open-labeled phase 2 clinical study. The aim of this study is to investigate the efficacy and safety of allogeneic natural killer cell (MG4101).
- Trial name
- NCT03349502
- Testing
- MG4101
- Where
- South Korea
- Volunteers
- 11 people
- Sponsor
- Seoul National University Hospital
Hematologic Malignancies
Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
This is a phase II study to assess the day 180 event free and overall survival after administration of a specified combination of fludarabine, busulfan, Total Body Irradiation (TBI), and thymoglobulin reduced intensity…
- Trial name
- NCT01622556
- Testing
- Fludarabine, Busulfan, Thymoglobulin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Virginia
Hepatocellular Carcinoma
to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)
To see the safety and efficacy of injecting MG4101 as a secondary treatment after curative liver resection on the patient with advanced HCC who has high risk of recurrence.
- Trial name
- MG4101 (NCT02008929)
- Testing
- MG4101
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- Samsung Medical Center
Myelofibrosis
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
The goal of this clinical research study is to learn if using a combination of fludarabine, busulfan, and antithymocyte globulin (ATG) can help to control myelofibrosis or myelodysplastic syndrome in patients receiving a bone…
- Trial name
- NCT00475020
- Testing
- Busulfan, Fludarabine, Thymoglobulin (ATG)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Stem Cell Transplantation, Hematopoietic, CMV Infection
MSC for Treatment of CMV Infection
The purpose of this study is to evaluate the efficacy of mesenchymal stem cells (MSC) in the treatment of refractory cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Conditions
- Stem Cell Transplantation, Hematopoietic, CMV Infection, Hematological Diseases
- Trial name
- NCT02083731
- Testing
- MSCs
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Stenosis; Bowel, Crohn Disease
Clinical Trial to Evaluate if the Laparoscopic Administration of Cells Derived From the Fatty Tissue Can Improve the Inflammatory Stenosis in Patient With Crohn's Disease
A phase II, national, multicenter, uncontrolled and open trial to evaluate the feasibility and safety of laparoscopic administration of adipose derived allogenic mesenchymals stem cells (adMSC), for the treatment of patients with…
- Trial name
- MEIC (NCT05521672)
- Testing
- Adipose derived allogenic mesenchymal stem cells (adAMSC)
- Where
- 3 sites in Spain
- Volunteers
- 2 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Recessive Dystrophic Epidermolysis Bullosa
Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa
The aim of this clinical trial is to investigate the efficacy (by monitoring overall improvement of EB symptoms) and safety (by monitoring adverse events) of three doses of allo-APZ2-EB administered intravenously to patients with…
- Trial name
- NCT03529877
- Testing
- allo-APZ2-EB
- Where
- 6 sites in United States, Austria and 3 more
- Volunteers
- 16 people
- Sponsor
- RHEACELL GmbH & Co. KG
Diabetic Foot Ulcer, Skin Lesions
Allogeneic Platelet Rich Plasma (PRP) to Treat Diabetic Foot Ulcers
Chronic skin ulcers pose a major health burden because of population aging and increased prevalence of chronic diseases such as diabetes.
- Conditions
- Diabetic Foot Ulcer, Skin Lesions, Allogeneic, PRP
- Trial name
- NCT06680856
- Testing
- PRP+HA, HA
- Where
- 2 sites in Italy
- Volunteers
- 72 people
- Sponsor
- Ospedale Policlinico San Martino
NHL, Relapsed, Adult, B-cell Lymphoma
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).
- Conditions
- NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma
- Trial name
- ANCHOR2 (NCT05487651)
- Testing
- KUR-502
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Athenex, Inc.
T2D
BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients
The aim of this preliminary study is to evaluate the safety and efficacy of bone-marrow mononuclear cells (BM-MNCs) and umbilical-cord tissue-derived mesenchymal stem cells (UC-MSCs) administration in type 2 diabetes patients
- Trial name
- NCT04501341
- Testing
- Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC, Intravenous Infusion of UC-MSC
- Where
- Indonesia
- Volunteers
- 15 people
- Sponsor
- Universitas Indonesia
Critical Limb Ischemia
Cell Therapy in Critical Limb Ischemia
Study drug and dosage form : Umbilical cord-derived mesenchymal stem cells (HB-MSC1) Dose and route of administration : 60 × 106 cells or 120 x 106 cells to be injected as 30 individual intramuscular injections, once at V0 within…
- Trial name
- CLI (NCT03994666)
- Testing
- allogeneic umbilical cord-derived mesenchymal stem cells
- Where
- France
- Volunteers
- 30 people
- Sponsor
- CHU de Reims
Graft Versus Host Disease
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
The purpose of this study was to test whether a new drug named visilizumab would decrease the severity of graft-versus-host disease in patients treated with a mismatched donor.
- Trial name
- NCT00720629
- Testing
- Visilizumab, Tacrolimus, Methotrexate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia, B-cell, Lymphoma, Hodgkins
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a procedure that transplants bone marrow cells (stem cells) from a matching donor into a recipient in order to allow the donor stem cells to produce…
- Conditions
- Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins, Lymphoma, B-Cell
- Trial name
- NCT01087294
- Testing
- Allogeneic stem cell transplant, Anti-CD19-chimeric-antigen-receptor-transduced T cells, Leukapheresis
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)
Eye Diseases, Retinitis Pigmentosa
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAION
This trial will study the safety and efficacy of intranasal delivery of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of non-arteritic ischemic optic neuropathy
- Conditions
- Eye Diseases, Retinitis Pigmentosa, Diabetic Retinopathy, Macular Degeneration
- Trial name
- NCT05147701
- Testing
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
- Where
- 2 sites in United States, Greece
- Volunteers
- 20 people
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Acute Graft Versus Host Disease Grade II-IV, Acute Graft vs Host Disease
Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy
An open-label, single-arm clinical trial to evaluate the safety and efficacy of gecacitinib tablets in patients with acute graft-versus-host disease (GVHD) who have failed or are intolerant to ruxolitinib-containing second-line…
- Trial name
- GRIT (NCT07197112)
- Testing
- Gecacitinib
- Volunteers
- 15 people
- Sponsor
- Ruijin Hospital
Leukemia, Medulloblastoma
Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant
The purpose of this study is to conduct an analysis of the influences of 1. conventional chemotherapy 2. high-dose chemotherapy followed by autologous stem cell transplant 3.
- Trial name
- NCT00231712
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Julius-Maximilians University
Stem Cell Leukemia of Unclear Lineage, Graft Versus Host Disease
Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease
To study the effect of ECP with Uvadex® in conjunction with a standard myeloablative conditioning regimen on the incidence of acute and chronic GvHD in patients undergoing an allogeneic related or unrelated BMT or PBSC…
- Trial name
- NCT01174940
- Testing
- extracorporeal photopheresis
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Kansas Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.